Can a talk therapy that boosts Self-Understanding prevent suicide?

NCT ID NCT07717320

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests whether a type of psychotherapy called mentalization-based therapy (MBT) can help adults who are at risk of suicide. Participants have recent suicidal thoughts or behaviors along with depression or anxiety. The therapy aims to improve how people understand their own and others' mental states, which may reduce suicidal feelings and improve emotional regulation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mentalization-based therapy (MBT), a type of psychotherapy that helps people understand their own and others' thoughts and feelings
What this could lead to
If successful, this could provide an evidence-based therapy for suicide prevention that can be used in public health systems.
What could go wrong
This is a validation study, not a large-scale trial, so results may not apply broadly. The therapy requires trained therapists, which may limit access.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age and consent * Presence of suicidal ideation or active behavior in the last month, assessed using the C-SSRS (e.g., intentional ideation, plan, or preparatory behavior) * Depressive or anxious symptoms (Score ≥ 10 on the PHQ-9, indicating at least moderate depressive symptoms, or Score ≥ 10 on the GAD-7, suggesting clinically significant anxiety.) * Availability and commitment to participate in the full assessment using all the aforementioned scales. Exclusion Criteria: * Clinical Safety (exclude and refer immediately) * Imminent suicide risk according to the C-SSRS (e.g., attempt within the last 7 days, current intentional plan, access to lethal means, and low ambivalence). * PHQ-9 item 9 = 3 ("almost every day") with clinical corroboration of imminent risk. * Current self-harm with lethality/high-harm moderator requiring acute restraint. * Refusal to establish a safety plan or allow emergency contact. * Acute Psychiatric Conditions/Contraindications of Assessment * Active psychosis or unstabilized manic episode. * Substance use disorder in intoxication or acute withdrawal (e.g., last 24-72 hours) that precludes valid assessment. * Uncontrolled risk of severe other-directed violence. * Medical or neurological conditions that preclude valid participation * Severe cognitive impairment (e.g., dementia, recent moderate-to-severe traumatic brain injury) that prevents understanding/answering scales. * Decompensated medical illness (e.g., desaturation, delirium, severe uncontrolled pain). * Unstable neurological condition (e.g., uncontrolled seizures). * Methodological interferences * Recent changes in baseline psychotropic medications within the last 2 weeks. * Concurrent intensive psychotherapy initiated within the last 4 weeks. * Simultaneous participation in another trial that could contaminate results. * Language other than that of the scales without available validation. * Logistical impossibility for follow-up (no telephone/stable contact; imminent relocation plan). * Legal aspects/consent * Incapacity to consent (legal or clinical) and no available representative. * Legal restrictions that prevent participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Suicide risk are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Consultorio Inter Cambio

    Panama City, Provincia de Panamá, Panama

  • Panama City Health Ministry Clinics

    Panama City, Provincia de Panamá, Panama

More trials for these conditions

Other studies related to the condition(s) this trial covers.